Key Points
- Ivan Hyep, Bicara's CFO, sold 13,555 shares on March 3 at an average price of $18.22 for about $246,972, reducing his direct stake by 8.53% to 145,355 shares (total CFO sales across March 3–4: 16,518 shares).
- Other senior insiders — including the COO (17,392 shares) and founder David Raben (~16,500 shares) — also sold sizable blocks around the same price, a pattern that may pressure sentiment; the stock trades near $18.64 with a market cap of about $1.02 billion and a consensus analyst target of $28.33 (Moderate Buy).
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $18.25, for a total value of $54,074.75. Following the completion of the transaction, the chief financial officer owned 145,355 shares of the company's stock, valued at approximately $2,652,728.75. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Ivan Hyep also recently made the following trade(s):
- On Tuesday, March 3rd, Ivan Hyep sold 13,555 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.22, for a total value of $246,972.10.
- On Thursday, January 22nd, Ivan Hyep sold 1,882 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.15, for a total value of $34,158.30.
Bicara Therapeutics Trading Down 1.1%
BCAX traded down $0.20 during trading on Friday, reaching $18.30. 174,055 shares of the company were exchanged, compared to its average volume of 486,713. Bicara Therapeutics Inc. has a 52 week low of $7.80 and a 52 week high of $19.71. The firm has a 50 day moving average of $16.43 and a 200 day moving average of $15.70. The stock has a market cap of $1.00 billion, a P/E ratio of -8.17 and a beta of -0.78.
Hedge Funds Weigh In On Bicara Therapeutics
Several large investors have recently made changes to their positions in the business. AQR Capital Management LLC purchased a new position in Bicara Therapeutics in the 1st quarter worth about $248,000. Woodline Partners LP raised its holdings in shares of Bicara Therapeutics by 26.5% during the first quarter. Woodline Partners LP now owns 348,690 shares of the company's stock valued at $4,543,000 after acquiring an additional 72,998 shares during the period. Nan Fung Trinity HK Ltd. acquired a new stake in shares of Bicara Therapeutics during the second quarter valued at approximately $3,185,000. Geode Capital Management LLC lifted its position in shares of Bicara Therapeutics by 36.8% in the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company's stock valued at $6,248,000 after acquiring an additional 180,833 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in Bicara Therapeutics by 119.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company's stock worth $75,000 after purchasing an additional 4,417 shares during the period.
Bicara Therapeutics News Summary
Here are the key news stories impacting Bicara Therapeutics this week:
- Neutral Sentiment: Company announced an inducement equity grant under Nasdaq Rule 5635(c)(4) — a routine hire-related award but one that can create modest dilution expectations. Bicara Therapeutics Announces Inducement Grant
- Neutral Sentiment: Short-interest entries posted for early March report “large increases” but show 0 shares/NaN changes — this appears to be a data error and is not informative about genuine shorting pressure.
- Negative Sentiment: CFO Ivan Hyep sold a total of 16,518 shares across March 3–4 at ~ $18.22–$18.25, reducing his stake (~2–8.5% reductions in separate filings). Large, disclosed CFO sales can weigh on sentiment. Ivan Hyep SEC Form 4
- Negative Sentiment: COO Ryan Cohlhepp sold 17,392 shares on March 3 at an average ~$18.16 (~7.8% reduction). Significant sales by operating leadership can signal personal liquidity-taking and may pressure the stock. Ryan Cohlhepp SEC Form 4
- Negative Sentiment: Insider David Raben sold ~16,500 shares in two transactions (200 and 16,300 shares) at ~ $18.45–$18.52, representing a ~22.8% reduction in one filing. Large founder/executive selling is commonly viewed negatively by the market. David Raben SEC Form 4
Analyst Upgrades and Downgrades
A number of research firms have issued reports on BCAX. Wedbush reissued an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. HC Wainwright reiterated a "buy" rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Citigroup assumed coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They issued an "outperform" rating on the stock. Mizuho raised Bicara Therapeutics to a "hold" rating in a research note on Thursday, December 18th. Finally, Citizens Jmp began coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They issued a "market perform" rating and a $31.00 price target for the company. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $28.33.
View Our Latest Report on Bicara Therapeutics
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
